ATE439442T1 - An der bildung einer in exon 5 defekten spleissvariante des presenilin-2-gens beteiligte nukleinsäure - Google Patents

An der bildung einer in exon 5 defekten spleissvariante des presenilin-2-gens beteiligte nukleinsäure

Info

Publication number
ATE439442T1
ATE439442T1 AT02743740T AT02743740T ATE439442T1 AT E439442 T1 ATE439442 T1 AT E439442T1 AT 02743740 T AT02743740 T AT 02743740T AT 02743740 T AT02743740 T AT 02743740T AT E439442 T1 ATE439442 T1 AT E439442T1
Authority
AT
Austria
Prior art keywords
nucleic acid
presenilin
exon
formation
gene
Prior art date
Application number
AT02743740T
Other languages
English (en)
Inventor
Masaya Tohyama
Taiichi Katayama
Takayuki Manabe
Kazunori Imaizumi
Yoko Ikeda
Original Assignee
Japan Science & Tech Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science & Tech Agency filed Critical Japan Science & Tech Agency
Application granted granted Critical
Publication of ATE439442T1 publication Critical patent/ATE439442T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
AT02743740T 2001-06-27 2002-06-27 An der bildung einer in exon 5 defekten spleissvariante des presenilin-2-gens beteiligte nukleinsäure ATE439442T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001195472A JP2003018991A (ja) 2001-06-27 2001-06-27 プレセニリン−２遺伝子エキソン５欠損型スプライシング異常の生成に関与する核酸
PCT/JP2002/006462 WO2003002742A1 (fr) 2001-06-27 2002-06-27 Acide nucleique participant a la formation de variant d'epissage defectueux du gene de la preseniline-2 exon 5

Publications (1)

Publication Number Publication Date
ATE439442T1 true ATE439442T1 (de) 2009-08-15

Family

ID=19033439

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02743740T ATE439442T1 (de) 2001-06-27 2002-06-27 An der bildung einer in exon 5 defekten spleissvariante des presenilin-2-gens beteiligte nukleinsäure

Country Status (8)

Country Link
US (1) US7364847B2 (de)
EP (1) EP1416048B1 (de)
JP (2) JP2003018991A (de)
AT (1) ATE439442T1 (de)
AU (1) AU2002346224B8 (de)
CA (1) CA2451959A1 (de)
DE (1) DE60233329D1 (de)
WO (1) WO2003002742A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
JP2009532674A (ja) * 2006-03-31 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 神経変性障害及びアルツハイマー病を治療するための、並びに正常な記憶を改善するための方法と組成物
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003192A2 (en) * 1995-07-07 1997-01-30 Darwin Molecular Corporation Chromosome 1 gene and gene products related to alzheimer's disease
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
EP1021533A1 (de) * 1997-10-01 2000-07-26 Aventis Pharma S.A. Kodierende nukleinsäuren für presenilin bindende proteine
ATE431850T1 (de) * 1998-05-21 2009-06-15 Mitsubishi Tanabe Pharma Corp Verfahren zur untersuchung von krankheiten des zentralen nervensystems und verfahren zum aufsuchen von arzneimitteln

Also Published As

Publication number Publication date
JP2003018991A (ja) 2003-01-21
JPWO2003002742A1 (ja) 2004-10-21
US7364847B2 (en) 2008-04-29
EP1416048A4 (de) 2005-01-26
CA2451959A1 (en) 2003-01-09
AU2002346224B2 (en) 2005-10-13
DE60233329D1 (de) 2009-09-24
EP1416048B1 (de) 2009-08-12
JP3930855B2 (ja) 2007-06-13
US20040267004A1 (en) 2004-12-30
WO2003002742A1 (fr) 2003-01-09
AU2002346224B8 (en) 2006-02-09
EP1416048A1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
DE59907520D1 (de) Verfahren zur kontinuierlichen Gewinnung von (Meth)acrylsäure
DE69633947D1 (de) Zwischenprodukte zur Herstellung von Metallproteinasehemmern
DE60001592D1 (de) Verfahren zur Reinigung von (Meth)acrylsäure
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
NO20022286D0 (no) Fasesementeringsverktöy for tynne hull og fremgangsmåte
ATE420192T1 (de) Verfahren zur verringerung der antigenität des adeno-assoziierten virus strukturproteins
EP1482962A4 (de) Verfahren zur behandlung von trx-vermittelten erkrankungen
DE60234425D1 (de) Verfahren zur optimaliserung von verkerhrsinformationsinhalt
DE69435162D1 (de) Chemisch modifizierter Gewebeinhibitor für Metalloproteasen Type 3 (TIMP-3)
FI972293L (fi) Useamman kuin yhden geenin yhteisekspressiomenetelmät
ATE268756T1 (de) Substituierte karbazole, verfahren zu ihrer herstellung und ihre verwendung als spla2- inhibitoren
DE69815110D1 (de) Verfahren zur reinigung von (meth)acrylsäure
ATE250077T1 (de) Steroid sulfataseinhibitoren, verfahren zu ihrer herstellung und verwendung
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
DE60211088D1 (de) Verfahren zur Herstellung von (Meth)acrylsäure
DE60030811D1 (de) Verfahren zur Ampifizierung von RNA
DE50303241D1 (de) Verfahren zur bereitstellung von abwesenheitsinformation
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE439442T1 (de) An der bildung einer in exon 5 defekten spleissvariante des presenilin-2-gens beteiligte nukleinsäure
DE60138164D1 (de) Verfahren zur elektrochemischen Bearbeitung von Kanälen
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
DE60220001D1 (de) Verfahren zur Herstellung von (Meth)acrylaten von Alkylimidazolidonen
ATE377078T1 (de) Dehiszenzgen und verfahren zur regulierung von dehiszenz
DE19983191T1 (de) Verfahren zur Steigerung der Effizienz von Geschäften

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties